SV Life Sciences (SVLS), an international life sciences venture capital firm with offices in Boston, San Francisco and London, has held the final closing of its SV Life Sciences Fund V with total commitments of over $523m.
Approximately 60% of capital commitments came from the United States and 40% from Europe and the rest of the world.
SVLSF V will be focused on providing start-up, early stage and expansion capital to life sciences companies in the United States and Europe. It will invest across a range of life sciences sectors, including biotechnology and pharmaceuticals, medical devices, healthcare services and healthcare information technology (HIT).
Investment size will typically be between $5m and $35m.
Managing partners of the SVLS investment team include James Garvey, Kate Bingham, Lutz Giebel, Eugene Hill, David Milne, and Michael Ross. They are supported by partners Darren Black, Graham Boulnois, David Guyer and Denise Marks as well as a strong group of venture partners.